AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
AbbVie (ABBV) raised its 2026 guidance on Friday as the biopharmaceutical company's immunology and n
Keep reading this article with Yahoo Finance Plus Silver
Silver
- Premium news Full access to Financial Times and MT Newswires articles
- Stock picks Expert picks from Motley Fool, Zacks, and Moby
- Research reports Expert analysis from Morningstar and Argus
